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Summary
Background About 15% of patients with endometrial cancer have high-risk features and are at increased risk of distant 
metastases and endometrial cancer-related death. We designed the PORTEC-3 trial to investigate the beneﬁ t of 
adjuvant chemoradiotherapy compared with radiotherapy alone for women with high-risk endometrial cancer.
Methods PORTEC-3 was a multicentre, open-label, randomised, international trial. Women with high-risk endometrial 
cancer were randomly allocated (1:1) to radiotherapy alone (48·6 Gy) in 1·8 Gy fractions ﬁ ve times a week or 
chemoradiotherapy (two cycles concurrent cisplatin 50 mg/m² and four adjuvant cycles of carboplatin area under the 
curve [AUC] 5 and paclitaxel 175 mg/m²) using a biased coin minimisation procedure with stratiﬁ cation for 
participating centre, lymphadenectomy, stage of cancer, and histological type. The primary endpoints of the PORTEC-3 
trial were overall survival and failure-free survival analysed in the intention-to-treat population. This analysis focuses 
on 2-year toxicity and health-related quality of life as secondary endpoints; analysis was done according to treatment 
received. Health-related quality of life was assessed with the European Organisation for Research and Treatment of 
Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) the cervix cancer module and chemotherapy and 
neuropathy subscales of the ovarian cancer module at baseline, after radiotherapy and at 6, 12, 24, 36, and 60 months 
after randomisation. Adverse events were graded with Common Terminology Criteria for Adverse Events version 3.0. 
The study was closed on Dec 20, 2013, after achieving complete accrual, and follow-up remains ongoing for the 
primary outcomes analysis. This trial is registered with ISRCTN.com, number ISRCTN14387080, and with 
ClinicalTrials.gov, number NCT00411138.
Findings Between Sept 15, 2006, and Dec 20, 2013, 686 women were randomly allocated in the PORTEC-3 trial. Of these, 
660 met eligibility criteria, and 570 (86%) were evaluable for health-related quality of life. Median follow-up was 
42·3 months (IQR 25·8–55·1). At completion of radiotherapy and at 6 months, EORTC QLQ-C30 functioning scales 
were signiﬁ cantly lower (worse functioning) and health-related quality of life symptom scores higher (worse symptoms) 
for the chemoradiotherapy group compared with radiotherapy alone, improving with time. At 12 and 24 months, global 
health or quality of life was similar between groups, whereas physical functioning scores remained slightly lower in 
patients who received chemoradiotherapy compared with patients who received radiotherapy alone. At 24 months, 
48 (25%) of 194 patients in the chemoradiotherapy group reported severe tingling or numbness compared with 11 (6%) 
of 170 patients in the radiotherapy alone group (p<0·0001). Grade 2 or worse adverse events were found during treatment 
in 309 (94%) of 327 patients in the chemoradiotherapy group versus 145 (44%) of 326 patients in the radiotherapy alone 
group, and grade 3 or worse events were found in 198 (61%) of 327 patients in the chemoradiotherapy group versus 
42 (13%) of 326 patients in the radiotherapy alone group (p<0·0001), with most of the grade 3 adverse events being 
haematological (45%). At 12 and 24 months, no signiﬁ cant diﬀ erences in grade 3 or worse adverse events were found 
between groups; only grade 2 or higher sensory neuropathy adverse events persisted at 24 months (25 [10%] of 240 patients 
in the chemoradiotherapy group vs one [<1%] of 247 patients in the radiotherapy alone group; p<0·0001).
Interpretation Despite the increased physician and patient-reported toxicities, this schedule of adjuvant chemotherapy 
given during and after radiotherapy in patients with high-risk endometrial cancer is feasible, with rapid recovery after 
treatment, but with persistence of patient-reported sensory neurological symptoms in 25% of patients. We await the 
analysis of primary endpoints before ﬁ nal conclusions are made.
Funding Dutch Cancer Society, Cancer Research UK, National Health and Medical Research Council, Project Grant, 
Cancer Australia Grant, Italian Medicines Agency, and Canadian Cancer Society Research Institute.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license.
Lancet Oncol 2016; 17: 1114–26
Published Online
July 7, 2016
http://dx.doi.org/10.1016/
S1470-2045(16)30120-6
See Comment page 1029
*Members listed in the appendix
Department of Radiation 
Oncology (S M de Boer MD, 
R A Nout MD, 
Prof C L Creutzberg MD), 
Department of Medical 
Statistics (Prof H Putter PhD), 
and Department of Pathology 
(Prof V T Smit PhD) Leiden 
University Medical Center, 
Leiden, Netherlands; 
Department of Clinical 
Oncology, Barts Health NHS 
Trust, London, UK 
(M E Powell MD); Division of 
Cancer Medicine, Peter 
MacCallum Cancer Centre, 
East Melbourne, VIC, Australia 
(L Mileshkin MD); Department 
of Surgical Sciences, 
Gynecologic Oncology, Città 
della Salute and S Anna 
Hospital, University of 
Torino, Torino, Italy 
(Prof D Katsaros MD); NCIC-CTG, 
Department of Obstetrics and 
Gynaecology, University of 
Sherbrooke, QC, Canada 
(Prof P Bessette MD); 
Department of Radiotherapy, 
Institut Gustave Roussy, 
Villejuif, France 
(C Haie-Meder MD); 
Department of Medical 
Oncology, Radboudumc, 
Nijmegen, Netherlands 
(P B Ottevanger MD); Cancer 
Research UK and UCL 
Cancer Trials Centre, UCL Cancer 
Institute, London, UK 
(Prof J A Ledermann MD); 
Division of Radiation Oncology 
& Cancer Imaging, 
Peter MacCallum Cancer Center, 
East Melbourne, VIC, Australia 
(P Khaw MD); Department of 
Radiation Oncology, Azienda 
Articles
www.thelancet.com/oncology   Vol 17   August 2016 1115
Ospedaliera della Provincia di 
Lecco, Italy (A Colombo MD); 
NCIC-CTG, Radiation Medicine 
Program, Princess Margaret 
Cancer Centre, Toronto, ON, 
Canada (Prof A Fyles MD); 
Department of Radiotherapy, 
Centre Hospitalier Régional 
Universitaire de Besançon, 
Besançon, France 
(M-H Baron MD); Institute of 
Cancer Sciences, University of 
Manchester, Manchester, UK 
(Prof H C Kitchener MD); 
Department of Gynaecologic 
Oncology, University Medical 
Center Groningen, University 
of Groningen, Groningen, 
Netherlands 
(Prof H W Nijman PhD); 
Department of Gynaecology 
and Obstetrics, and GROW—
School for Oncology and 
Developmental Biology, 
Maastricht University Medical 
Center, Maastricht, 
Netherlands 
(Prof R F Kruitwagen PhD); and 
Comprehensive Cancer Center 
The Netherlands, Leiden, 
Netherlands 
(K W Verhoeven-Adema PhD)
Correspondence to:
Dr Stephanie M de Boer, 
Department of Radiation 
Oncology, Leiden University 
Medical Center, 2300 RC Leiden, 
Netherlands
s.m.de_boer.onco@lumc.nl
See Online for appendix
Introduction
Endometrial cancer is most commonly diagnosed at an 
early stage and most women are cured with surgery 
alone.1 Adjuvant treatment for early stage endometrial 
cancer is based on risk factors, such as histological 
grade, myometrial invasion, age, and lymph-vascular 
space invasion.2–4 The PORTEC-2 trial5,6 showed the 
eﬃ  cacy of vaginal brachytherapy in reducing vaginal 
recurrence of endometrial cancer in women with 
high-intermediate-risk endometrial cancer. About 15% 
of all patients with endometrial cancer have high-risk 
disease (classiﬁ ed as stage I grade 3 cancer with deep 
invasion or with substantial lymph-vascular space 
invasion, stage II or III cancer, or cancer with 
non-endometrioid histology).1 Higher incidence of 
distant metastases and endometrial cancer-related 
deaths has been reported for these patients.7–10 Serous 
and clear cell endometrial cancer are histological 
subtypes with poorer prognosis because of their high 
risk of metastasis, but when diagnosed at an early stage 
seem to have similar survival rates to grade 3 
endometrioid endometrial cancer.11
Pelvic external beam radiotherapy has been the 
standard adjuvant treatment for women with high-risk 
endometrial cancer for several decades. Randomised 
trials12,13 comparing adjuvant chemotherapy with 
external beam radiotherapy have shown similar rates of 
relapse and survival. Because increased pelvic relapse 
has been reported with adjuvant chemotherapy alone, 
use of pelvic radiotherapy combined with adjuvant 
chemotherapy has been advocated.14,15 The RTOG9708 
phase 2 trial16 investigated a combination of external 
beam radiotherapy with two cycles of cisplatin, followed 
by four cycles of cisplatin-paclitaxel in 46 women with 
high-risk endometrial cancer. 4-year overall survival 
was 85% and disease-free survival was 81%, and 
acceptable toxicity was reported. The randomised 
NSGO-EC-9501/EORTC-55991 trial compared external 
beam radiotherapy alone with external beam 
radiotherapy and four cycles of platinum-based 
chemotherapy. This trial was published in a pooled 
analysis with the MaNGO ILIADE-III trial17 with a 
combined total of 534 patients, and showed statistically 
signiﬁ cantly improved progression-free survival with 
the addition of chemotherapy. None of these trials have 
reported detailed toxicity or quality of life data for 
chemoradiotherapy in endometrial cancer. Establishing 
both the beneﬁ t of more intensive adjuvant treatment 
and the eﬀ ect in terms of added morbidity and eﬀ ect on 
health-related quality of life are essential.
We initiated the international PORTEC-3 trial to 
investigate survival beneﬁ t and toxicities of chemotherapy 
Research in context
Evidence before this study
We searched PubMed between Jan 1, 1980, and Dec 31, 2006, 
with the terms “endometrial cancer” AND “radiation therapy” 
AND “chemotherapy” AND “toxicity” AND “quality of life”, with a 
ﬁ lter for clinical trials, clinical studies, and multicentre studies. 
We identiﬁ ed eight relevant publications, mostly small studies of 
which most used a sequential schedule with various 
chemotherapy drugs, and only two trials assessed combined 
chemotherapy and radiotherapy. The studies only very brieﬂ y 
mentioned acute toxicities and no long-term data for adverse 
events were available. Studies which compared radiotherapy with 
chemotherapy did not report on quality of life and only limited 
data for adverse events were available. The phase 2 RTOG 9708 
trial, which assessed toxicity of the combined chemotherapy and 
radiotherapy schedule, and on which the PORTEC-3 treatment 
schedule was based, reported a 98% completion rate among 
46 patients. Acute grade 3 adverse events were reported in 
12 (27%) patients and grade 4 adverse events in one (2%) patient 
during concurrent chemoradiotherapy and in nine patients (21%) 
and 26 patients (62%) during adjuvant chemotherapy. 
For chronic toxicities, grade 3 adverse events were found in 
seven (16%) patients and grade 4 adverse events were found in 
two (5%) patients; no quality of life data were available.
Added value of this study
To our knowledge, this is the ﬁ rst randomised study reporting 
adverse events and quality of life of this combined 
chemotherapy and radiotherapy schedule. We assessed the 
toxicity and quality of life of patients with high-risk endometrial 
cancer treated in the international randomised PORTEC-3 trial 
with pelvic radiotherapy alone or the combination of 
radiotherapy with concurrent (cisplatin) and adjuvant 
(carboplatin-paclitaxel) chemotherapy. The combination of 
chemotherapy and radiotherapy had signiﬁ cant eﬀ ect on 
adverse events and quality of life during and after treatment. 
However, rapid recovery occurred between 6–12 months after 
randomisation, without diﬀ erence in grade 3 adverse events at 
12 and 24 months. Grade 2 neurological adverse events 
persisted in 10% of patients in the chemoradiotherapy group 
versus <1% of patients in the radiotherapy group alone, with 
25% of patients in the chemoradiotherapy group reporting 
“quite a bit” or “very much” tingling or numbness.
Implications of all the available evidence
Combined adjuvant chemoradiotherapy for women with 
high-risk endometrial cancer is feasible, with increased rates 
of adverse events and a higher eﬀ ect on health-related quality 
of life during and after treatment. Persisting neurological 
symptoms were the only adverse event that diﬀ ered 
signiﬁ cantly between groups 12 months after randomisation. 
Final analysis of the PORTEC-3 trial is awaited to determine 
the trade-oﬀ  of the survival beneﬁ t versus eﬀ ect on quality of 
life of added chemotherapy in women with high-risk 
endometrial cancer. 
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combined with external beam radiotherapy compared 
with external beam radiotherapy alone for high-risk 
endometrial cancer. Final analysis of overall survival and 
failure-free survival is awaited, as the required number of 
events has not yet been reached. We did this analysis to 
establish and compare adverse events and patient-
reported symptoms and health-related quality of life in 
women with high-risk endometrial cancer treated in 
PORTEC-3.
Methods
Study design and participants
PORTEC-3 was a multicentre, open-label, randomised 
intergroup trial led by the Dutch Gynaecological 
Oncology Group. Patients were enrolled in the study by 
the radiation oncologists from the participating centres 
in the following international participating groups: 
the Medical Research Council and the National Cancer 
Research Institute (UK), the Australia New Zealand 
Gynaecological Oncology Group (Australia and 
New Zealand), Mario Negri Gynecologic Oncology 
group (Italy), Fedegyn (France) and National Cancer 
Institute of Canada Clinical Trials Group (Canada).
Patients were eligible for inclusion in this trial if 
they had International Federation of Gynecology and 
Obstetrics 2009 categorised stage IA grade 3 endometrial 
carcinoma with myometrial invasion and with 
documented lymph-vascular space invasion; stage IB 
grade 3; stage II, stage IIIA, or IIIC (or IIIB if parametrial 
invasion only); serous or clear cell histology with stage 
IA (with invasion), IB, II, or III. Eligible patients also 
had to have adequate WHO performance scores 
(WHO score 0–2); bone marrow (white blood cell count 
≥3·0 cells × 10⁹/L, platelets ≥100 × 10⁹/L); liver function 
(bilirubin ≤1·5 × upper limit of normal [ULN], aspartate 
aminotransferase concentration ≤2·5 × ULN, or alanine 
aminotransferase concentration ≤2·5 × ULN); and 
kidney function (creatinine clearance >60 mL/min 
calculated according to Cockroft18 or >50 mL/min EDTA 
clearance) and be aged older than 18 years. Exclusion 
criteria were having uterine sarcoma, previous 
malignancy less than 10 years ago, receipt of previous 
pelvic radiotherapy, hormonal or chemotherapy, gross 
cervical involvement with radical hysterectomy, 
inﬂ ammatory bowel disease, residual macroscopic 
tumour, impaired renal or cardiac function, neuropathy 
grade 2 or worse, hearing impairment grade 3 or worse, 
or congenital hearing disorder.
    Surgery comprised of total abdominal or laparoscopic 
hysterectomy with bilateral salpingo-oophorectomy. 
Lymphadenectomy was left at the discretion of the 
participating centres. For serous or clear cell carcinoma, 
staging including omentectomy; peritoneal biopsies and 
lymph node sampling were recommended. Upfront 
central pathology review was undertaken by the 
reference gynaecological pathologists of the participating 
groups to conﬁ rm ﬁ nal eligibility for the study.
Written informed consent was obtained from all 
patients. The protocol was approved by the Dutch Cancer 
Society, and the ethics committees of the participating 
groups or centres. Participating groups obtained their 
institutional review board and ethics approvals and were 
funded by separate grants. The protocol is available 
online.
Randomisation and masking
Patients were randomly allocated (1:1) to receive either 
chemoradiotherapy or radiotherapy alone. Treatment 
was allocated with a biased coin minimisation procedure, 
with stratiﬁ cation according to participating centre, 
lymphadenectomy (yes or no), stage, and histological 
type. The outcome of the allocation was computer 
generated and not predictable by the investigators. 
Patients were registered and randomised by the 
participating group’s data centres and treatment was 
assigned with a web-based application. The trial number 
and assigned treatment were generated immediately by 
the randomisation programme and conﬁ rmed by email 
to the investigators. Participants and investigators were 
not masked to treatment allocation.
Procedures
Pelvic radiotherapy was given in both treatment groups 
(48·6 Gy in 1·8 Gy fractions, ﬁ ve times a week for 
5·5 weeks). The clinical target volume included the 
proximal vagina, parametrial tissues, and internal, 
external, and common iliac lymph node regions up to the 
upper S1 level (the level of promontory). The clinical 
target volume was extended for lymph node involvement. 
In case of cervical involvement, a brachytherapy boost 
was given. Treatment had to be started preferably within 
4–6 weeks after surgery, but no later than 8 weeks after 
surgery. Treatment breaks were avoided and could not 
exceed 2 days, overall treatment time for radiotherapy 
could not exceed 50 days.
Patients in the chemoradiotherapy group received two 
cycles of cisplatin 50 mg/m² in the ﬁ rst and fourth week 
of radiotherapy, followed by four cycles of carboplatin 
area under the curve (AUC) 5 and paclitaxel 175 mg/m² at 
21-day intervals (and a 28-day interval between the second 
concurrent and ﬁ rst adjuvant cycle). This schedule was 
based on the RTOG9708 trial,16 with substitution of 
cisplatin with carboplatin in the adjuvant phase. In the 
event of haematological, renal, or other toxicities, cisplatin 
was postponed for 1 week. If recovery required more than 
1 week or in the case of neurological adverse events of 
grade 2 or worse, cisplatin was discontinued. Carboplatin 
was postponed or stopped in the case of severe 
haematological toxicity. Carboplatin dose was reduced to 
AUC 4 if recovery to grade 1 was attained at two weeks. 
Paclitaxel was postponed if grade 2 neuropathy was 
reported and stopped if recovery exceeded 1 week or 
grade 3 neuropathy developed. After recovery or reduction 
to grade 1 adverse events, paclitaxel dose was reduced to 
For the protocol see 
www.clinicalresearch.nl/portec3
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135 mg/m². Carboplatin and paclitaxel were delayed for 
other grade 3–4 toxicities, and discontinued if there was 
no recovery or reduction to grade 1 adverse events. 
Patients were assessed every 3 months for the ﬁ rst 
24 months, and every 6 months up to 5 years. Long-term 
outcome evaluation at 7 and 10 years was obtained, 
preferably by follow-up visits, or by information from 
their general practitioner. At each follow-up visit, a patient 
history with emphasis on treatment-related morbidity, 
and physical and pelvic examination was done. Chest 
radiograph, blood count, and chemistry tests (including 
Ca-125) were obtained once a year, up to 5 years after 
randomisation. 
Toxicity was graded with the Common Terminology 
Criteria for Adverse Events version 3.0 and was assessed 
at baseline (after surgery), completion of radiotherapy, at 
each chemotherapy cycle, and at 6-month follow-up 
intervals from randomisation until 5 years and at 7 and 
10 years. Health-related quality of life questionnaires 
were completed at baseline after surgery and after 
completion of radiotherapy, at 6-month intervals from 
randomisation until 24 months, and at 36 and 60 months. 
Health-related quality of life was assessed with the 
European Organisation for Research and Treatment of 
Cancer Quality of Life Questionnaire Core 30 (EORTC 
QLQ-C30, version 3.0).19 As the EORTC endometrial 
module was not yet available, the cervix 24 (CX24) module 
was used, with added chemotherapy and neuropathy 
subscales from the ovarian 28 (OV28) module.20,21 Higher 
scores on functional and global health-related quality of 
life scales represented better levels of functioning. On the 
symptom subscales, higher scores reﬂ ected higher levels 
of symptoms.
All adverse events were graded and adverse events of 
grade 2 or worse were reported on case record forms, 
irrespective of the relation with study treatment. For mild 
(grade 1) toxicities, the patient-reported health-related 
quality of life symptoms were used. Serious adverse events 
were reported within 24 h, specifying adverse event grade 
and relation to study treatment. Time from randomisation 
was used to compare severity and duration of toxicities 
between the treatment groups; importantly, the 6-month 
timepoint was about 1 month after completion of 
chemotherapy in the chemoradiotherapy group.
Outcomes
Primary endpoints were overall survival and failure-free 
survival, with failure deﬁ ned as any relapse or death 
related to endometrial carcinoma. Secondary endpoints 
were treatment-related toxicity, health-related quality of 
life, and pelvic or distant relapse.
Statistical analysis
The PORTEC-3 trial was powered (80%) to detect a 
diﬀ erence of 10% (HR 0·67) in 5-year overall survival 
(65% to 75%); for this, 198 events were required, and a 
minimum of 655 patients. The analysis plan for the second 
primary endpoint failure-free survival will be added in an 
amendment to the trial protocol. Primary and secondary 
outcomes not involving toxicity or health-related quality of 
life were analysed by intention to treat. Safety outcomes 
were assessed in all patients who received at least one cycle 
of chemotherapy and 1 week of radiotherapy (in the 
chemoradiotherapy group) and 1 week of radiotherapy 
(in the radiotherapy alone group). Although no speciﬁ c 
power calculations were done for the toxicity and 
health-related quality of life analysis, the minimum 
required number of 655 patients ensured suﬃ  cient power 
to detect clinically relevant diﬀ erences. Toxicity and quality 
of life were analysed according to treatment received.  
Formal tests for the diﬀ erences in relapse and survival 
rates between the two groups were done with the 
Kaplan-Meier method, the log-rank test, and Cox 
regression analysis. The median follow-up of all patients 
was estimated by the inverse Kaplan-Meier method. 
We measured toxicity at baseline, at completion of 
radiotherapy, every cycle of concurrent and adjuvant 
chemotherapy, and 6, 12, 18, and 24 months; quality of 
life was measured at baseline, completion of radiotherapy, 
and 6, 12, 18, and 24 months after randomisation. During 
follow-up, toxicity and quality of life forms completed 
within a 3-month window before or after the designated 
timepoint were included. The time during treatment was 
deﬁ ned as all toxicity forms related to radiotherapy and 
all cycles of concurrent and adjuvant chemotherapy.
Criteria to be removed from the analysis were 
ineligibility or withdrawal of informed consent before 
the start of treatment. Patients were evaluable for 
health-related quality of life analysis if they had completed 
baseline and at least one follow-up form. Missing data for 
patients were handled as missing-at-random, assuming 
that missing data was not related to the values of the 
unobserved variables. This is an assumption that is not 
possible to verify statistically.22 The prevalence of toxicity 
graded according to the Common Terminology Criteria 
for Adverse Events version 3.0 was calculated at each 
timepoint. Per adverse event, the maximum grade per 
patient was calculated (worst ever by patient). 
The maximum grade over the entire course of therapy 
and follow-up for any adverse events and for the 
individual patient was used as a summary of toxicity. 
Fisher’s Exact test was used to compare toxicity between 
the two treatment groups. A prespeciﬁ ed health-related 
quality of life analysis was done according to the EORTC 
Quality of Life Group guidelines.23 Baseline scores of 
both treatment groups were compared with a t test, or 
Armitage trend test for single items. A linear mixed 
model was used to obtain estimates of the EORTC 
QLQ-C30, CX24, and OV28 subscales at each of the 
timepoints, with patient as random eﬀ ect and time 
(categorical), treatment, and their interaction between 
time and treatment as ﬁ xed eﬀ ects. Single items were 
analysed with (binary) logistic regression with random 
eﬀ ect, combining scores of 1–2 (“not at all” and “a little”) 
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and 3–4 (“quite a bit” and “very much”). The diﬀ erence in 
health-related quality of life between the groups over 
time was tested by a joint Wald test of all treatment-by-time 
interaction in the linear or logistic mixed model. To guard 
against false-positive results because of multiple testing, 
a two-sided p value of less than or equal to 0·01 was 
considered statistically signiﬁ cant.
Guidelines for the interpretation of clinically relevant 
changes to EORTC QLQ-C30 scores were applied.24,25 
For scales not included in the guidelines, changes were 
assessed according to Osoba and colleagues.26 Statistical 
analyses were done with SPSS, version 20.0, and 
R statistical software, version 3.2.1.
A Data and Safety Monitoring Board oversaw the study. 
After discussion within the trial management group and 
with approval of the Data and Safety Monitoring Board, 
the decision was made to submit for publication. 
The study was closed on Dec 20, 2013, after achieving 
complete accrual; follow-up is continuing. This trial is 
registered with ISRCTN.com, number ISRCTN14387080, 
and with ClinicalTrials.gov, number NCT00411138.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The central data manager (KWV-A), 
the principal investigator (CLC) and associated 
investigators (SMdB, RAN), and trial statistician (HP) 
had full access to the data. The Dutch Cancer Society 
Scientiﬁ c Review Board approved the trial design. 
The corresponding author and chief investigator had full 
access to all of the data and the ﬁ nal responsibility to 
submit for publication.
Results
Between Sept 15, 2006, and Dec 20, 2013, we recruited 
686 patients to the PORTEC-3 trial recruited. Of these 
patients, 13 did not meet inclusion criteria (ﬁ gure 1). 
Reasons for exclusion were diﬀ erent stage, macroscopic 
residual disease, low creatinine clearance, impaired 
hearing (≥grade 3), or diﬀ erent histological type. Another 
13 patients withdrew their informed consent immediately 
after randomisation and were excluded from this 
analysis, leaving 660 patients (330 in each group) for 
intention-to-treat analysis. Seven (1%) of 660 patients 
refused the allocated treatment (ﬁ ve in the 
chemoradiotherapy group and two in the radiotherapy 
alone group) and switched to the other treatment group 
(ﬁ gure 1). For analysis of toxicity and health-related 
quality of life these seven patients were assessed by 
treatment received, resulting in 327 patients in the 
chemoradiotherapy group and 333 patients in 
the radiotherapy alone group. Median follow-up at the 
time of analysis for all patients was 42·3 months 
(IQR 25·8–55·1); 42·1 months (25·7–54·7) in the 
chemoradiotherapy group and 42·4 months (27·1– 55·4) 
in the radiotherapy alone group. With ongoing follow-up, 
487 (74%) patients (240 in the chemoradiotherapy group 
and 247 in the radiotherapy alone group) had reached the 
2-year timepoint by the time of this analysis.
Patient characteristics were well balanced between 
the chemoradiotherapy and radiotherapy alone groups 
(table 1). Lymphadenectomy was performed in 203 (62%) 
in the chemoradiotherapy group and in 205 (62%) 
patients in the radiotherapy alone group. Radiotherapy 
was discontinued by one (<1%) patient who received 
chemoradiotherapy because of disease progression and 
by ﬁ ve (2%) patients who received radiotherapy alone 
because of toxicity (n=4) and an accidental fall with femur 
fracture (n=1). A brachytherapy boost was given in 
149 (46%) of 327 patients in the chemoradiotherapy 
group and 156 (47%) of 333 patients in the radiotherapy 
alone group. Treatment completion details are shown in 
table 1. Chemotherapy was discontinued in 61 (19%) 
patients because of drug-related toxicity in 31 (9%) 
patients, patient decision in 20 (6%) patients, disease 
progression in seven (2%) patients, or for other reasons 
in three (1%) patients. Dose reductions were reported if 
the dose was reduced by more than 10%. At least one 
dose reduction of cisplatin (to 40 mg/m²) was recorded 
for ﬁ ve (2%) patients, of carboplatin (from AUC 5 to 
AUC 4) for 22 (7%) patients, and of paclitaxel (from 
175 mg/m² to 135 mg/m²) for 34 patients (10%). Analysis 
of primary outcomes is ongoing and will be reported in a 
future publication.
For 570 (86%) of 660 patients, a baseline questionnaire 
and at least one follow-up questionnaire was received, 
292 for the chemoradiotherapy group and 278 in the Figure 1: Trial proﬁ le
328 received radiotherapy 325 received chemoradiotherapy
330 included in intention-to-treat
 primary analysis
330 included in intention-to-treat
 primary analysis
333 included in toxicity analysis of
 radiotherapy group
327 included in toxicity analysis of
 chemoradiotherapy group
2 received radiotherapy and
 chemotherapy
5 received radiotherapy only
13 excluded 
 4 immediate informed consent 
 withdrawal
 9 ineligible 
13 excluded 
 9 immediate informed consent 
 withdrawal
 4 ineligible 
330 assigned to radiotherapy 
 (intention to treat) 
686 patients randomly assigned
330 assigned to chemotherapy and
 radiotherapy (intention to treat)  
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radiotherapy alone group. These 570 responders were 
assessable for health-related quality of life. 90 (14%) of 
660 patients could not be assessed for health-related 
quality of life, mostly because of a missing form at 
baseline, whereas some questionnaires were invalid 
because of missing dates of completion or a completion 
date after the ﬁ rst day of radiotherapy. At 24 months, 
health-related quality of life scores of 364 (55%) patients 
had been received, which corresponds to 64% of the 
570 responders: (194 [66%] of 292 patients in the 
chemoradiotherapy group and 170 [61%] of 278 patients 
in the radiotherapy alone group). Questionnaire 
response rates for each timepoint are given in the 
appendix (p 3). WHO performance score was diﬀ erent 
between those who responded to the questionnaire and 
those who did not, with WHO 0–1 recorded in 565 (99%) 
of 570 patients who responded versus 85 (94%) of 
90 patients who did not respond, and WHO score of 2 or 
more in ﬁ ve (1%) patients who responded versus 
ﬁ ve (6%) patients who did not respond (p=0·007). 
No other diﬀ erences were seen in patient characteristics 
between responders and non-responders (data not 
shown). 89% of the responders completed all items of 
the EORTC QLQ-C30 in the returned questionnaires, 
80% completed all items of the CX24 subscale, 92% 
completed all non-sexual items, and 91% of the 
responders completed all items of the OV28 subscale.
Adverse event incidence during and after treatment is 
summarised in table 2. A comprehensive list of adverse 
events is provided in the appendix (p 4). At baseline, no 
signiﬁ cant diﬀ erences in adverse events were recorded 
between groups. Baseline grade 2 adverse events were 
reported for 109 (33%) of 327 patients who received 
chemoradiotherapy and 93 (29%) of 326 patients who 
received radiotherapy alone, and grade 3–4 toxicities 
were reported in 33 (10%) patients who received 
chemoradiotherapy and 28 (9%) patients who received 
radiotherapy alone. No deaths occurred during 
treatment; two patients (one in each group) died shortly 
after treatment: one patient in the chemoradiotherapy 
group died from pneumonia after surgery for bowel 
obstruction because of adhesions; one elderly patient in 
the radiotherapy alone group died 3 weeks after 
radiotherapy because of pneumonia and subsequent 
multiorgan failure. The death of both patients was not 
related to the study treatment as reported by the treating 
physician.
During the study, including whole treatment 
and follow-up period, 89 (27%)  of 327 patients in 
the chemoradiotherapy group versus 154 (47%) of 
326 patients in the radiotherapy alone group had a 
maximum toxicity of grade 2 adverse events. Grade 3 
adverse events or worse were reported for 229 (70%) of 
327 patients in the chemoradiotherapy group versus 
112 (34%) of 326 patients in the radiotherapy alone 
group (ﬁ gure 2). During treatment, grade 2 or worse 
adverse events were found in 309 (94%) of 327 patients 
Chemoradiotherapy 
(n=327)
Radiotherapy alone 
(n=333)
Age at randomisation (years)
Median 62·5 (56·5–68·0) 61·9 (55·9–68·1)
<60 years 125 (38%) 143 (43%)
60–69 years 143 (44%) 129 (39%)
≥70 years 58 (18%) 61 (18%)
Missing data* 1 0
FIGO 2009 stage
Stage I 95 (30%) 97 (31%)
Stage II 79 (25%) 88 (28%)
Stage III 144 (45%) 131 (41%)
Missing data* 9 17 
Histological grade and type
EEC grade 1 44 (14%) 45 (14%)
EEC grade 2 81 (25%) 80 (24%)
EEC grade 3 102 (32%) 111 (34%)
Non-endometrioid 83 (26%) 77 (23%)
Mixed 13 (4%) 17 (5%)
Missing data* 4 3 
WHO performance score
0–1 319 (98%) 327 (98%)
≥2 5 (2%) 5 (2%)
Missing data* 3 1
Comorbidity
Diabetes 45 (14%) 36 (11%)
Hypertension 115 (35%) 105 (32%)
Cardiovascular 30 (9%) 20 (6%)
Type of surgery
Total abdominal hysterectomy and bilateral 
salpingo-oopherectomy
82 (25%) 87 (26%)
Total abdominal hysterectomy and bilateral 
salpingo-oopherectomy plus lymph node dissection or 
full staging (lymph node dissection with omentectomy 
and peritoneal biopsies)
153 (47%) 146 (44%)
Total laparoscopic hysterectomy and bilateral 
salpingo-oopherectomy
41 (13%) 40 (12%)
Total laparoscopic hysterectomy and bilateral 
salpingo-oopherectomy plus lymph node dissection or 
full staging (lymph node dissection with omentectomy 
and peritoneal biopsies)
50 (15%) 59 (18%)
Missing data* 1 1 
Treatment completion
Radiotherapy 326 (100%) 328 (98%)
Brachytherapy boost 149 (46%) 156 (47%)
1 cycle cisplatin 325 (99%) ··
2 cycles cisplatin 305 (93%) ··
1 cycle carboplatin/paclitaxel 303 (93%)/303 (93%) ··
2 cycles carboplatin/paclitaxel 295 (90%)/295 (90%) ··
3 cycles carboplatin/paclitaxel 279 (85%)/267 (82%) ··
4 cycles carboplatin/paclitaxel 262 (80%)/235 (72%) ··
Data are median (IQR) or n (%). *Missing values are not included in the percentage calculation. FIGO=International 
Federation of Gynaecology and Obstetrics. EEC=endometrioid endometrial carcinoma.
Table 1: Characteristics of as-treated population by treatment group
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in the chemoradiotherapy group versus 145 (44%) of 
326 patients in the radiotherapy alone group (p<0·0001); 
grade 3 or higher were found in 198 (61%) patients in 
the chemoradiotherapy group versus 42 (13%) patients 
in the radiotherapy alone group (p<0·0001; ﬁ gure 2, 
table 2). Most grade 3 or worse toxicities in both groups 
during treatment were haematological, gastrointestinal, 
or pain related. During treatment, grade 3 or worse 
sensory neuropathy was reported in 22 (7%) patients 
and motor neuropathy was reported in four (1%) 
patients, all in the chemo radiotherapy group. At 12 and 
24 months after treatment, no signiﬁ cant diﬀ erence in 
grade 3 or worse adverse events was seen between the 
groups. The most important persisting toxicity was 
grade 2 or worse sensory neuropathy at 12 months in 
30 (10%) patients in the chemoradiotherapy group 
versus three (1%) patients in the radiotherapy group, 
and 25 (10%) patients in the chemoradio therapy 
group versus one (<1%) patient in the radiotherapy 
alone group at 24 months (p<0·0001). No signiﬁ cant 
diﬀ erences in gastrointestinal, genitourinary, or haema-
tological toxicities were seen at 12 and 24 months. 
Slightly worse auditory toxicity and bone-related pain 
were found in patients treated with chemoradiotherapy 
at 12 months (appendix p 4).
Results of the EORTC QLQ-C30 functioning subscales 
and global health status, and mean scores for CX24 and 
OV28 subscales are summarised in table 3. All single 
symptom items are reported in appendix (p 7). During 
treatment, patients treated with chemoradiotherapy 
scored signiﬁ cantly lower on most EORTC functioning 
scales; 10–20-point lower scores on physical, role, and 
social functioning, and global health status compared 
with patients treated with radiotherapy alone. However, 
rapid recovery was reported, and at 12 months physical 
functioning was the only signiﬁ cant diﬀ erence between 
the two treatment groups (ﬁ gure 3).
The most frequently reported severe (“quite a bit” or 
“very much”) symptoms at 6 months were tingling or 
numbness in 111 (52%) of 214 patients in the 
chemoradiotherapy group versus 15 (7%) of 209 patients 
in the radiotherapy alone group (p<0·0001), muscle or 
joint pain in 80 (37%) of 214 patients in the 
chemoradiotherapy group versus 45 (22%) of 207 patients 
in the radiotherapy alone group (p=0·002), fatigue in 
66 (31%) of 210 patients versus 36 (17%) patients 
(p=0·0004), weakness in the arms or legs in 76 (36%) of 
214 patients versus 24 (11%) of 209 patients (p<0·0001), 
and hair loss in 88 (44%) of 200 patients versus eight (4%) 
of 208 patients (p<0·0001), with events in the 
chemoradiotherapy group signiﬁ cantly higher in all 
these cases. At 24 months, most diﬀ erences had subsided 
and the most frequent symptoms did not diﬀ er much 
from baseline (ﬁ gure 4). Tingling or numbness was still 
signiﬁ cantly higher in patients in the chemoradiotherapy 
group (48 [25%] of 194 vs 11 [6%] of 170 patients; 
p<0·0001).
Patient-reported lymphoedema did not diﬀ er between 
the two treatment groups (appendix p 7). Severe 
lymphoedema was reported more frequently by patients 
who had undergone a lymphadenectomy (both treatment 
groups combined): 47 (17%) of 276 patients after 
lymphadenectomy versus 13 (8%) of 163 patients 
without lymphadenectomy at 12 months (p=0·01) and 
38 (16%) of 237 patients versus 14 (11%) of 127 patients 
at 24 months (p=0·2). After lymphadenectomy, severe 
lymphoedema was reported by 18 (15%) of 120 patients 
in the chemoradiotherapy group and 20 (17%) of 
117 patients in the radiotherapy alone group at 
24 months (p=0·84), compared with seven (10%) of 
69 patients and seven (12%) of 58 patients, respectively, 
who had no lympha denectomy (p=0·69; appendix, p 9). 
No signiﬁ cant diﬀ erences in sexual functioning score 
were seen between the treatment groups, measured 
according to CX24 (table 3). Sexual activity was low in 
Figure 2: Incidence of the maximum physician-reported adverse event 
grades per patient for each timepoint at baseline, during treatment and 
at 6, 12, and 24 months follow-up in the chemoradiotherapy group (A) 
and the radiotherapy alone group (B)
*Total not 333 because of missing forms.
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Questionnaire timepoints p value
Baseline After radiotherapy 6 months 12 months 18 months 24 months Changes over 
time
Diﬀ erence 
between groups
Diﬀ erence between 
groups over time
EORTC functioning scales
Physical functioning
Chemoradiotherapy 81·3 76·3 72·5 80·1 79·5 80·0 <0·0001 <0·0001 <0·0001
Radiotherapy alone 84·6 83·1 86·5 85·9 84·8 85·5 ·· ·· ··
Role functioning
Chemoradiotherapy 70·4 66·5 67·8 79·3 78·7 79·8 <0·0001 <0·0001 <0·0001
Radiotherapy alone 73·7 74·5 84·7 85·1 83·7 85·8 ·· ·· ··
Emotional functioning
Chemoradiotherapy 74·4 76·9 77·1 79·1 80·3 81·1 <0·0001 0·21 0·74
Radiotherapy alone 77·6 81·7 80·6 82·2 82·0 84·7 ·· ··
Cognitive functioning
Chemoradiotherapy 87·0 81·8 79·8 84·5 82·8 85·1 <0·0001 0·002 0·008
Radiotherapy alone 88·0 85·6 86·9 86·8 86·2 85·7 ·· ·· ··
Social functioning
Chemoradiotherapy 78·1 73·5 74·4 84·2 85·4 85·4 <0·0001 <0·0001 <0·0001
Radiotherapy alone 80·4 78·7 88·3 89·0 87·7 91·2 ·· ·· ··
Global health status/quality of life
Chemoradiotherapy 86·2 77·3 81·8 89·8 87·3 89·6 <0·0001 <0·0001 <0·0001
Radiotherapy alone 87·1 85·3 89·6 90·1 90·7 90·5 ·· ·· ··
EORTC symptom scales
Fatigue
Chemoradiotherapy 28·9 42·0 38·4 27·7 28·9 26·9 <0·0001 <0·0001 <0·0001
Radiotherapy alone 26·5 34·1 23·7 23·7 22·7 22·5 ·· ·· ··
Nausea and vomiting
Chemoradiotherapy 3·8 14·1 8·8 4·7 3·8 3·5 <0·0001 <0·0001 <0·0001
Radiotherapy alone 4·0 10·0 5·5 6·9 4·8 6·7 ·· ·· ··
Pain
Chemoradiotherapy 18·4 21·2 23·3 20·8 19·9 19·0 0·06 0·09 0·24
Radiotherapy alone 17·0 19·6 16·6 16·6 16·0 16·7 ·· ·· ··
CX24 subscales
Symptom experience* 
Chemoradiotherapy 9·6 16·2 12·1 11·6 11·9 11·7 <0·0001 0·66 0·55
Radiotherapy alone 9·5 16·8 12·1 12·6 11·1 11·9 ·· ·· ··
Body image
Chemoradiotherapy 11·6 16·6 24·9 16·0 15·0 15·6 <0·0001 <0·0001 <0·0001
Radiotherapy alone 9·9 12·8 12·7 12·4 11·6 11·2 ·· ·· ··
Sexual functioning†
Chemoradiotherapy 13·2 22·3 18·3 19·9 17·2 21·4 0·05 0·36 0·34
Radiotherapy alone 9·5 22·4 22·0 23·6 22·7 25·5 ·· ·· ··
OV28 subscales
Chemotherapy‡
Chemoradiotherapy 7·9 18·7 31·2 14·7 14·0 13·2 <0·0001 <0·0001 <0·0001
Radiotherapy alone 6·2 11·2 12·1 12·5 12·3 11·5 ·· ·· ··
Peripheral neuropathy
Chemoradiotherapy 5·5 14·2 47·0 31·4 28·5 27·8 <0·0001 <0·0001 <0·0001
Radiotherapy alone 5·5 8·8 12·8 12·9 12·6 13·2 ·· ·· ··
All subscales responses were converted to 0 to 100 scales (according to the EORTC guidelines). Higher scores for functioning items and global quality of life scale represent a better level of functioning. For the symptom 
scales, a higher score reﬂ ects a higher level of symptoms. EORTC QLQ-C30=European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. CX24=cervix 24. OV28=ovarian 28. 
*Subscale symptom experience included abdominal cramps, controlling bowels, blood in stool, urinary frequency, dysuria, urinary incontinence, diﬃ  culty emptying bladder, lower back pain, vaginal irritation or 
soreness, vaginal discharge, and abnormal vaginal bleeding. †Responses to the questions of this subscale were only expected if the respondent was indicated to be sexually active. ‡Subscale chemotherapy included hair 
loss, taste change, muscle aches or pains, hearing problems, urinary frequency, or skin problems.
Table 3: Patient reported health-related quality of life symptoms using the EORTC QLQ-C30 and subscales of cervix 24 and ovarian 28 over the treatment and 2-year follow-up
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both groups, but was slightly higher in the radiotherapy 
alone group during treatment (p=0·006), and similar 
thereafter (see appendix p 8). 
Discussion
This analysis of toxicity and 2-year health-related quality 
of life in the PORTEC-3 trial for women with high-risk 
endometrial cancer clearly shows that adjuvant chemo-
therapy given during and after pelvic radiotherapy 
causes signiﬁ cantly higher incidence of severe 
adverse events and of patient-reported symptoms, and a 
decreased level of patient functioning and health-related 
quality of life compared with radiotherapy alone. 
However, rapid recovery was seen, with reduction of all 
incidence and grades of adverse events between 6 and 
12 months after randomisation, and without signiﬁ cant 
diﬀ erences in grade 3 or worse adverse events at 12 and 
24 months. The only remaining signiﬁ cant diﬀ erence in 
adverse events at 12 and 24 months was increased 
grade 2 or worse sensory neuropathy in the chemo-
radiotherapy group compared with the radiotherapy 
alone group (25 [10%] of 240 vs 1 [<1%] of 247), with 
health-related quality of life showing “quite a bit” or 
“very much” tingling or numbness reported by 25% of 
patients in the chemoradiotherapy group versus 6% of 
patients in the radiotherapy alone group. After 
24 months, patients treated with chemoradiotherapy 
group still had slightly lower physical functioning 
scores, which might partly be because of their higher 
rate of peripheral neuropathy. Most functioning scores 
showed small remaining diﬀ erences (0–6 points) in 
mean scores, which are of borderline clinical relevance 
according to the guidelines for interpretation of the 
EORTC QLQ-C30.24,25
Patients treated in the chemoradiotherapy group 
reported signiﬁ cantly more tingling or numbness, 
muscle or joint pain, fatigue, weakness in the arms and 
legs, and hair loss at 6 months. All of these items, 
together with a longer treatment duration and more 
intense treatment because of the chemotherapy could 
be contributing to lower quality of life scores. The 
association between individual symptoms and overall 
quality of life will be a subject of further investigation.
The 6-month timepoint when most severe adverse 
events and worst quality of life were reported by patients 
receiving chemoradiotherapy was only 1 month after 
completion of chemotherapy, whereas patients treated 
with radiotherapy alone already had 4 months of recovery 
time. These results represent the toxicity proﬁ les of the 
patients in the two treatment groups and provide a 
realistic view of the time with toxicity in the 
chemoradiotherapy group, which is of relevance for 
patient counselling when considering chemotherapy.
Data for the toxicity of chemotherapy in advanced or 
metastatic endometrial cancer are mainly available from 
the randomised trials27 in which doxorubicin and 
Figure 3: Patient functioning subscales and single-item symptom EORTC QLQ-C30 scores for physical functioning (A), social functioning (B), global health 
status or quality of life (C), and fatigue (D)
For physical functioning, social functioning, and global health status or quality of life, a higher score indicated a higher level of functioning or activity, and for fatigue, 
a higher score indicates a higher level of symptoms. Error bars show 95% CI. EORTC QLQ-C30=European Organisation for Research and Treatment of Cancer Quality of 
Life Questionnaire Core 30. p time=diﬀ erence in quality of life scores over time within the whole treatment group. p treatment=diﬀ erence between the 
two treatment groups. p time by treatment=diﬀ erence between the two treatment groups over time. 
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cisplatin with or without paclitaxel were used. Incidence 
of sensory neuropathy in those trials during 
chemotherapy was signiﬁ cantly higher than in the 
PORTEC-3 trial, with 27% of patients having grade 2 
adverse events and 12% of patients having grade 3 
neuropathy when treated with the doxorubicin, cisplatin, 
and paclitaxel triplet combination. Results of the 
randomised GOG-20928 trial in which the triplet 
chemotherapy was compared with carboplatin-paclitaxel 
are pending, but an abstract reported similar eﬃ  cacy 
with a better toxicity proﬁ le of carboplatin-paclitaxel 
(NCT00063999). The GOG-249 trial29 compared pelvic 
radiotherapy alone with vaginal brachytherapy followed 
by three cycles of carboplatin and paclitaxel in 
patients with stage I–II endometrial cancer with 
high-intermediate-risk or high-risk features. First results 
at a median follow-up of 24 months showed no 
diﬀ erences in recurrence-free and overall survival, with 
more acute toxicity in the chemotherapy group. Data for 
health-related quality of life are pending.
Data for toxicity and health-related quality of life 
of women treated with carboplatin or paclitaxel 
chemotherapy are mainly available from ﬁ rst-line 
therapy in ovarian cancer trials. Comparison is relevant, 
as patients with ovarian cancer are of similar age and 
have also had previous pelvic surgery, and the 
combination of radiation and chemotherapy was 
expected to be more toxic than chemotherapy alone. 
Ovarian cancer trials with a 3-weekly schema of 
carboplatin AUC6 and paclitaxel 175–180 mg/mL 
reported mainly grade 3–4 haematological toxicities, 
with similar grades of haematological toxicity and 
febrile neutropenia in the MITO-7 trial30 compared 
with PORTEC-3, and higher grades reported in the 
JGOG-3016 trial.31 Additionally with this 3-weekly 
schema, grade 3–4 sensory and motor neuropathy were 
reported in 6% and 4% respectively in JGOG 3016, 
compared with 7% and 1% in PORTEC-3, and 3% had 
any grade 3–4 neuropathy in the MITO-7 trial.
At 24 months after randomisation, patient-reported 
sensory neuropathy remained signiﬁ cantly worse in the 
chemoradiotherapy group than in the radiotherapy alone 
group. A population-based study in ovarian cancer 
survivors reported peripheral neuropathy (as measured 
with EORTC-OV28) in 51% of patients treated with 
chemotherapy versus 27% of participants treated without 
chemotherapy.32 Neuropathy is a common symptom in 
the general population, increasing with age and with the 
prevalence of diabetes.33 Women with higher levels of 
neuropathy reported lower levels of functioning and 
quality of life, and more fatigue.32
Completion rates for chemotherapy were 93% for 
cisplatin, 80% for carboplatin, and 72% for paclitaxel, 
with dose reductions in 7% of carboplatin and 10% of 
paclitaxel cycles. Completion was lower than in 
RTOG9708,16 but reﬂ ects clinical practice in a large 
multicentre trial. In MITO-7,30 90% of the patients 
treated carboplatin-paclitaxel received all six cycles; but 
with dose reductions in 36%. No signiﬁ cant diﬀ erences 
were seen between the treatment groups in sexual 
functioning. Similar to health-related quality of life 
ﬁ ndings in the PORTEC-1 and PORTEC-2 trials, baseline 
sexual activity just after surgery and during treatment 
was low, with improvement over time, but sexual activity 
in this elderly patient group remained lower compared 
with population data.6 
The current endometrial cancer module (EN24) was 
not yet available when the PORTEC-3 trial was 
Figure 4: Patient responses on single-item symptom scales over time for tingling or numbness (A), muscle or 
joint pain (B), and diarrhoea (C) in the chemoradiotherapy group and the radiotherapy alone group
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designed. Therefore the CX24 module has been used 
with the subscale of chemotherapy from OV28, which 
has not been speciﬁ cally tested for endometrial cancer. 
This could be a possible limitation to the study, 
although the EN24 module is very similar to CX24, with 
some of the same chemotherapy-related questions as in 
OV28 included.34
PORTEC-3 assessed both physician-reported and 
patient-reported toxicities. Limited agreement between 
patient and physician reported scoring of toxicities has 
been shown, with signiﬁ cant physician under-reporting 
of lower grade toxicities.35 In the PORTEC-3 study, 
physicians were required to report grade 2 or worse 
adverse events to focus on more severe toxicities, and 
patient-reported outcomes were used for mild toxicities. 
Although patient-reported and physician-reported 
symptoms use diﬀ erent scales, similar trends in types of 
symptoms over time were seen.
Both the PORTEC-3 trial and the GOG-258 trial 
used the same combined chemotherapy–radiotherapy 
schedule, but in comparison with radiotherapy alone and 
chemotherapy alone, respectively. The toxicity and 
health-related quality of life outcomes need to be 
considered in the light of ﬁ nal survival data. If these 
trials were to show the combined treatment to be 
superior, future trials should focus on treatment 
schedules with least toxicity. For ovarian cancer, several 
trials have been done to compare diﬀ erent (weekly) 
infusion schedules to achieve a balance between 
optimum therapy and acceptable toxicity.30,31
Overall, combined adjuvant chemotherapy and 
radiotherapy for high-risk endometrial cancer caused 
signiﬁ cantly higher incidence of severe adverse events 
and reduced health-related quality of life during and 
after treatment compared with radiotherapy alone, but 
with rapid recovery. The most persisting and troublesome 
symptom was sensory neuropathy, rated as “quite a bit” 
or “very much” by 25% of patients at 24 months. 
This schedule of combined chemotherapy and 
radiotherapy is feasible, and these data are essential for 
patient counselling and shared decision making on 
adjuvant chemotherapy. The question remains whether 
the impact in terms of toxicities will be outweighed by 
an overall or failure-free survival beneﬁ t. Final analysis 
of the PORTEC-3 and GOG258 trials are awaited, to 
determine the beneﬁ t of chemoradiotherapy in women 
with high-risk endometrial cancer.
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